DE60129599T2 - Faktor xiii in kombination mit faktor ix zur behandlung von hämophilie b - Google Patents
Faktor xiii in kombination mit faktor ix zur behandlung von hämophilie b Download PDFInfo
- Publication number
- DE60129599T2 DE60129599T2 DE60129599T DE60129599T DE60129599T2 DE 60129599 T2 DE60129599 T2 DE 60129599T2 DE 60129599 T DE60129599 T DE 60129599T DE 60129599 T DE60129599 T DE 60129599T DE 60129599 T2 DE60129599 T2 DE 60129599T2
- Authority
- DE
- Germany
- Prior art keywords
- factor
- hemophilia
- plasma
- factor xiii
- xiii
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 229940012444 factor xiii Drugs 0.000 title claims abstract description 38
- 229960004222 factor ix Drugs 0.000 title claims abstract description 36
- 238000011282 treatment Methods 0.000 title description 6
- 208000031220 Hemophilia Diseases 0.000 title description 5
- 208000009292 Hemophilia A Diseases 0.000 title description 5
- 102100022641 Coagulation factor IX Human genes 0.000 claims abstract description 49
- 108010071289 Factor XIII Proteins 0.000 claims abstract description 38
- 108010076282 Factor IX Proteins 0.000 claims abstract description 35
- 208000009429 hemophilia B Diseases 0.000 claims abstract description 14
- 239000003814 drug Substances 0.000 claims description 6
- 229940079593 drug Drugs 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 230000000694 effects Effects 0.000 description 13
- 230000037396 body weight Effects 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 108010000499 Thromboplastin Proteins 0.000 description 5
- 102000002262 Thromboplastin Human genes 0.000 description 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 208000032843 Hemorrhage Diseases 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 description 3
- 206010053567 Coagulopathies Diseases 0.000 description 3
- 230000035602 clotting Effects 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000023597 hemostasis Effects 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 2
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- 108010048049 Factor IXa Proteins 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 229940031422 benefix Drugs 0.000 description 2
- 208000034158 bleeding Diseases 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000003114 blood coagulation factor Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000015271 coagulation Effects 0.000 description 2
- 238000005345 coagulation Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 229940012414 factor viia Drugs 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 108010012557 prothrombin complex concentrates Proteins 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000005995 Aluminium silicate Substances 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- AFSDNFLWKVMVRB-UHFFFAOYSA-N Ellagic acid Chemical compound OC1=C(O)C(OC2=O)=C3C4=C2C=C(O)C(O)=C4OC(=O)C3=C1 AFSDNFLWKVMVRB-UHFFFAOYSA-N 0.000 description 1
- ATJXMQHAMYVHRX-CPCISQLKSA-N Ellagic acid Natural products OC1=C(O)[C@H]2OC(=O)c3cc(O)c(O)c4OC(=O)C(=C1)[C@H]2c34 ATJXMQHAMYVHRX-CPCISQLKSA-N 0.000 description 1
- 229920002079 Ellagic acid Polymers 0.000 description 1
- 108010062466 Enzyme Precursors Proteins 0.000 description 1
- 102000010911 Enzyme Precursors Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108010061932 Factor VIIIa Proteins 0.000 description 1
- 108010014173 Factor X Proteins 0.000 description 1
- 201000007371 Factor XIII Deficiency Diseases 0.000 description 1
- 108010080805 Factor XIa Proteins 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 108010088842 Fibrinolysin Proteins 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- 108010056902 Mononine Proteins 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108010094028 Prothrombin Proteins 0.000 description 1
- 102100027378 Prothrombin Human genes 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 208000026578 Severe hemophilia B Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000035508 accumulation Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 238000011374 additional therapy Methods 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000009190 disseminated intravascular coagulation Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 229960002852 ellagic acid Drugs 0.000 description 1
- 235000004132 ellagic acid Nutrition 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 125000002642 gamma-glutamyl group Chemical group 0.000 description 1
- 208000031169 hemorrhagic disease Diseases 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- FAARLWTXUUQFSN-UHFFFAOYSA-N methylellagic acid Natural products O1C(=O)C2=CC(O)=C(O)C3=C2C2=C1C(OC)=C(O)C=C2C(=O)O3 FAARLWTXUUQFSN-UHFFFAOYSA-N 0.000 description 1
- 230000004784 molecular pathogenesis Effects 0.000 description 1
- 229940090053 mononine Drugs 0.000 description 1
- 206010028320 muscle necrosis Diseases 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 229940039716 prothrombin Drugs 0.000 description 1
- 238000012207 quantitative assay Methods 0.000 description 1
- 238000009256 replacement therapy Methods 0.000 description 1
- 238000007423 screening assay Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 230000009724 venous congestion Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/45—Transferases (2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24736200P | 2000-11-10 | 2000-11-10 | |
| US247362P | 2000-11-10 | ||
| PCT/US2001/047144 WO2002038167A2 (en) | 2000-11-10 | 2001-11-08 | Use of factor xiii for treating hemophilia b |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE60129599D1 DE60129599D1 (de) | 2007-09-06 |
| DE60129599T2 true DE60129599T2 (de) | 2008-04-17 |
Family
ID=22934628
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE60129599T Expired - Lifetime DE60129599T2 (de) | 2000-11-10 | 2001-11-08 | Faktor xiii in kombination mit faktor ix zur behandlung von hämophilie b |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP1351706B1 (enExample) |
| JP (1) | JP2004513150A (enExample) |
| AT (1) | ATE367824T1 (enExample) |
| AU (1) | AU2002226004A1 (enExample) |
| CA (1) | CA2429018A1 (enExample) |
| DE (1) | DE60129599T2 (enExample) |
| ES (1) | ES2288524T3 (enExample) |
| WO (1) | WO2002038167A2 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008510476A (ja) | 2004-08-27 | 2008-04-10 | ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト | 生物学的材料からのｘｉｉｉ因子ポリペプチドの精製 |
| JP5086093B2 (ja) | 2004-11-23 | 2012-11-28 | ジモジェネティクス、インコーポレイテッド | 組換え型ヒトｘｉｉｉ因子の精製 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2423988A (en) * | 1987-08-17 | 1989-03-09 | Liposome Company, Inc., The | A sponge enzyme having transglutaminase-like activity |
| WO2001085198A1 (en) * | 2000-05-10 | 2001-11-15 | Novo Nordisk A/S | tHARMACEUTICAL COMPOSITION COMPRISING A FACTOR VIIA AND A FACTOR XIII |
-
2001
- 2001-11-08 AT AT01993470T patent/ATE367824T1/de not_active IP Right Cessation
- 2001-11-08 AU AU2002226004A patent/AU2002226004A1/en not_active Abandoned
- 2001-11-08 WO PCT/US2001/047144 patent/WO2002038167A2/en not_active Ceased
- 2001-11-08 ES ES01993470T patent/ES2288524T3/es not_active Expired - Lifetime
- 2001-11-08 CA CA002429018A patent/CA2429018A1/en not_active Abandoned
- 2001-11-08 EP EP01993470A patent/EP1351706B1/en not_active Expired - Lifetime
- 2001-11-08 JP JP2002540749A patent/JP2004513150A/ja active Pending
- 2001-11-08 DE DE60129599T patent/DE60129599T2/de not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| AU2002226004A1 (en) | 2002-05-21 |
| EP1351706B1 (en) | 2007-07-25 |
| ES2288524T3 (es) | 2008-01-16 |
| WO2002038167A3 (en) | 2002-08-22 |
| CA2429018A1 (en) | 2002-05-16 |
| DE60129599D1 (de) | 2007-09-06 |
| JP2004513150A (ja) | 2004-04-30 |
| WO2002038167A2 (en) | 2002-05-16 |
| EP1351706A2 (en) | 2003-10-15 |
| ATE367824T1 (de) | 2007-08-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69828462T2 (de) | Verwendung von APC, in Kombination mit Blutplättchenaggregationshemmer, zur Behandlung thrombothischer Störungen | |
| DE69130289T2 (de) | Therapeutische verwendung von actin-bindenden verbindungen | |
| Avvisati et al. | Tranexamic acid for control of haemorrhage in acute promyelocytic leukaemia | |
| Ludlam et al. | Factor VIII and fibrinolytic response to deamino‐8‐D‐argenine vasopressin in normal subjects and dissociate response in some patients with haemophilia and von Willebrand's disease | |
| DE60115422T2 (de) | PHARMAZEUTISCHE ZUSAMMENSETZUNG ENTHALTEND EINEN FAKTOR VIIa UND EINEN TFPI-INHIBITOR | |
| Blum et al. | Parathyroid hormone responses during spontaneous hypocalcemia and induced hypercalcemia in cows | |
| DE68913050T2 (de) | Antithrombotische zusammensetzung. | |
| Thompson et al. | Prolonged bleeding times and hypofibrinogenemia in dogs after infusion of hydroxyethyl starch and dextran | |
| Tyigate et al. | Metabolism and Distribution of Fibrinogen 11. FIBRINOGEN TURNOVER IN POLYCYTHAEMIA, THROMBOCYTOSIS, HAEMOPHILIA A, CONGENITAL AFIBRINOGENAEMIA AND DURING STREPTOKINASE THERAPY | |
| Yamamoto et al. | Antithrombotic treatment in livedo vasculitis | |
| DE60129599T2 (de) | Faktor xiii in kombination mit faktor ix zur behandlung von hämophilie b | |
| DE69905489T2 (de) | Protein c zur behandlung von sichelzellanämie und thalassämie | |
| DE60128130T2 (de) | Verwendung des blutgerinnungsfaktors xiii für die behandlung der hämophilie a | |
| DE69532123T2 (de) | Thrombolytische zusammensetzungen | |
| US20090036361A1 (en) | Use of Blood Coagulation Factor XIII for Treating Hemophilia A | |
| DE69009706T2 (de) | Thrombolytische Mittel. | |
| DE69833727T2 (de) | Verfahren zur Behandlung der Gefässerkrankungen mit aktiviertem Protein C | |
| Schepers et al. | Efficacy and safety of low‐dose intravenous versus intramuscular vitamin K in parenteral nutrition patients | |
| DE69724818T2 (de) | Medizinische Verwendung des scuPA/suPAR Komplexes | |
| DE69930419T2 (de) | Verwendung von menschliche protein c zur herstellung eines arzneimittels zur behandlung von heparininduzierter thrombozytopenie | |
| Hata et al. | Blood coagulation and fibrinolysis in SART-stressed (repeated cold-stressed) rats and drug effects on the altered hemostatic parameters | |
| US20070015709A1 (en) | Method for treating hemophilia B | |
| US20200147188A1 (en) | Therapeutic composition containing antithrombin gamma | |
| US3268405A (en) | 4-aminomethyl-cyclohexane-1-carboxylic acid for inhibiting the activation of plasmin | |
| DE69916493T2 (de) | Verwendung von protein c zur behandlung von thrombozytopenischer purpura und hämolytisches urämisches syndrom |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition |